Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally.
We are pushing the frontiers to explore the intersection between immunology and machine learning.
Immune TCR repertoires hold the answers to therapeutics and diagnostics. The big data challenge is to interpret complex immune data that also addresses racial bias in clinical algorithms.
Etcembly is delivering novel solutions to diseases through the synergy of empirical validation and informatics.
Using unexploited novel machine learning methods, Etcembly has developed a proprietary machine learning platform (EMLy™) that interprets TCR repertoires for the effective design of personalised therapeutics.
Deep Neural Architecture integrated with the database form the basis of EMLy’s computation in novel diagnostic and theraputic solutions.
Through the insights of combining the two key hemispheres of immunology and applying machine learning and immune pattern recognition, we able to:
Predict and target diseases more rapidly
Design personalised therapeutics across all racial groups
Determine immunological versus biological age
Create diagnostics that facilitate patient stratification
Determine how the immune system is driven by external factors such as ethnicity and age
Our technology is designed to bring benefits to:
Lean drug discovery for large pharmaceuticals